GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Connect Biopharma Holdings CNTB · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.73

-0.41%

Close of 6 Nov 2026, in USD

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$64,000

FY2019FY2025

Net income

−$55.5m

FY2019FY2025

Free cash flow

−$51.6m

FY2019FY2025

Shareholders' equity

$42.0m

FY2019FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Revenue$64,000$26.0m—————
Gross profit$64,000$26.0m−$988,000−$153,147———
Research and development$37.8m$29.3m$53.0m$14.4m$12.0m$3.4m$2.3m
Operating income−$58.1m−$22.5m−$69.1m−$17.7m−$14.6m−$4.5m−$2.4m
Net income−$55.5m−$15.6m−$62.1m−$17.5m−$30.1m−$17.7m−$3.6m
Diluted earnings per share-1.00-0.28-1.13-0.32-0.56-0.32-0.07

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Total assets$56.1m$101.3m$127.4m$25.9m$43.2m$3.8m$1.1m
Cash and short-term investments$44.3m$93.7m$118.3m$22.6m$39.8m$3.6m$1.0m
Total liabilities$14.1m$9.1m$25.9m$2.5m$2.8m$7.4m$2.1m
Debt$322,000$154,000$465,000$3.0m$800,000$2.07bn$643.9m
Shareholders' equity$42.0m$92.2m$101.5m$23.4m$40.5m−$3.6m−$919,049
Shares outstanding56m55m55m55m54m55m56m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Cash from operations−$51.2m−$23.6m−$47.9m−$14.8m−$81.0m−$3.8m−$1.9m
Capital spending−$434,000−$750,000−$294,000−$636,342−$7.1m−$348,370−$23,110
Free cash flow−$51.6m−$24.4m−$48.2m−$15.4m−$88.0m−$4.2m−$2.0m
Dividends paid————−$36,109——

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
Revenue$2.9m$169,000$16,000$16,000$48,000—$698,000$1.2m
Gross profit$2.9m—$16,000—$48,000—$698,000—
Operating income−$37.2m−$19.6m−$15.5m−$17.7m−$13.4m−$11.4m−$9.6m−$13.8m
Net income−$36.7m−$19.4m−$15.1m−$17.2m−$12.9m−$10.3m−$8.9m−$12.9m
Diluted earnings per share-0.58-0.31-0.27-0.31-0.23-0.18-0.16-0.23
Cash from operations−$31.0m−$16.0m−$11.0m−$17.0m−$12.0m−$9.0m−$15.0m−$13.0m
Total assets$43.5m$60.1m$56.1m$67.4m$82.7m$92.7m$101.3m—
Cash and short-term investments$31.5m—$44.3m—$71.8m—$93.7m—
Debt$393,000—$322,000—$350,000—$154,000—
Shareholders' equity$26.9m$42.6m$42.0m$55.4m$71.3m$82.9m$92.2m—

Growth per year

Compound annual rate

3 years5 years10 years
Operating income48.5%66.8%—
Net income46.8%25.6%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%———
Operating margin-308.6%———
Net margin-272.5%———

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Price to earnings-2.8-4.9-1.1-1.7-2.4
Price to sales—2.9———

Share price return

Finished calendar years

20252024202320222021
Return136%13%97%-63%-42%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1-to-1 reverse split · 3 Sept 2025

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.